ResearchMoz include new market research report"Asthma Therapeutics Market to 2019 – Breakthrough Biologics to Enhance Treatment of Severe Asthma and Drive Market Growth " to its huge collection of research reports.
Albany, NY -- (SBWIRE) -- 10/09/2013 -- Asthma Market to 2019”. The asthma market is forecast to grow marginally over the forecast period across the leading eight developed nations, from $16.6 billion in 2012 to a projected value of $21.6 billion in 2019. This growth is expected despite the generic erosion facing the leading brands, and is a consequence of new market entrants and a disease prevalence that continues to rise, albeit not at rates as high as have been seen in the past. Some new, costly asthma therapies could be set to enter the asthma market, including GlaxoSmithKline’s (GSK’s) recently approved Relvar (fluticasone/vilanterol), and multiple monoclonal antibodies (mAbs).
Click Here To Download Detail Report - http://www.researchmoz.us/asthma-therapeutics-market-to-2019-%E2%80%93-breakthrough-biologics-to-enhance-treatment-of-severe-asthma-and-drive-market-growth-report.html
These include reslizumab, mepolizumab and lebrikizumab, which are being developed by Teva, GSK and Roche respectively. The mAbs, in particular, have the potential to change the asthma treatment landscape, most notably with regards to severe forms of the disease. Although such therapy may only play the role of an alternative treatment in the asthma treatment algorithm, their ability to reduce exacerbation rates has strong clinical and commercial value.
The report assesses the current asthma market, and forecasts market trends to 2019, analyzing key drivers and barriers. The areas covered include the following:
A disease introduction, which defines the disease, including symptoms, diagnosis and treatment
Analysis of the landscape of the asthma market, including a comparison of the efficacy and safety of the most prominent brands
Detailed analysis of the asthma pipeline, including, among other parameters, details of drug distribution by phase, molecule type and mechanism of action. The asthma clinical trial landscape is then analyzed, with a particular emphasis on failure rates across phases as well as trends in clinical trial size and duration, and by mechanism of action. This section also includes single-product forecasts for the most promising pipeline drugs.
An in-depth forecasting model for the asthma market, which considers the current marketed therapies, in addition to the potential market entry of new products. The model consists of a projected outcome, with high and low variance results, depending on the potential performance of pipeline therapies.
Analysis of strategic consolidations within the asthma indication, including co-development and licensing agreements
An overview of the drivers and barriers for the asthma market
Browse Other Reports By GBI Research - http://www.researchmoz.us/publisher/gbi-research-2.html
Reasons to Buy
Primarily, the report will enable clients to establish a strong understanding of the asthma indication, helping to identify and understand market opportunities and the emerging competitive environment. It will also enable you to:
Understand the asthma pipeline and the factors that indicate that it is becoming more innovative. This is highlighted by the presence of numerous biologics in the pipeline, which look set to have a major impact upon the asthma market.
Observe detailed profiles for promising pipeline products, including revenue forecasts, and gain insights into how they are likely to compete in the market and who their main competitors will be.
Follow the trends in asthma clinical trial size and duration in relation to industry averages. In addition, the report will enable you to assess the potential risk of future developmental programs for asthma therapeutics, depending on the mechanism of action, by considering the recorded clinical trial failure rates.
Observe the potential growth patterns expected for the asthma market over the forecast period, and identify which countries are expected to contribute the most to this growth.
Related Reports -
Mammography Equipment Market to 2019
Mammography Equipment Market to 2019 – Growth Driven by Technical Advances in Digital Radiography that Enhance Workflow and Improve Breast Cancer Detection looks at the market, competitive landscape, and trends for the two mammography equipment market segments: digital radiography mammography equipment and film-screen mammography equipment. It provides comprehensive information on the key trends affecting these segments, and key analytical content on the market dynamics. The report also reviews the competitive landscape, analyzes each segment’s pipeline products and gives details of important Merger and Acquisition (M&A) deals. It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
Computed Tomography Systems Market to 2019
Computed Tomography Systems Market to 2019 – Lower Radiation Dose and Improved Workflow in Advanced CT Systems to Increase Adoption Rates” looks at the market, competitive landscape, and trends for three computed tomography systems segments: high slice computed tomography systems, mid slice computed tomography systems and low slice computed tomography systems. The report provides comprehensive information on the key trends affecting these segments and analyzes the market dynamics. It also reviews the competitive landscape and the details of important M&A deals. It is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research’s team of industry experts.
Type 2 Diabetes Market to 2019 -
Type 2 Diabetes Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019”. There is currently a large number of blood glucose-lowering drugs in the crowded type 2 diabetes market indicated for the treatment of chronically high blood glucose. The market is led by Lantus, which achieved global sales amounting to $6.4 billion in 2012. Over the forecast period from 2012 to 2019, the safer, more efficacious newer classes of drug (GLP-1 agonists, DPP-4 Inhibitors and SGLT-2 inhibitors) are expected to capture substantial market shares, largely replacing older classes such as sulfonylureas and thiazolidinediones. Additionally, a variety of novel drugs belonging to these newer classes are due to enter the market, and are expected to offer a moderate improvement in terms of efficacy and safety. The price of these new therapies is expected to be high, but this is unlikely to hinder their uptake.
ResearchMoz (http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
For More Information Kindly Contact:
Browse Blog - http://latestmarketstudy.blogspot.com/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)